Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Tuspetinib by Aptose Biosciences for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...
Data Insights
Tuspetinib by Aptose Biosciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...